This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.
Iftekhar Kalsekar, PhD
Advertisement
Articles by Iftekhar Kalsekar, PhD
Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Retrospective analysis of medical and pharmacy claims for patients diagnosed with schizophrenia or bipolar disorder in 24 state Medicaid programs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Patient Portal Messages Outpace Office Visits
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5